Tirzepatide as a possible trigger of bullous pemphigoid: A case report.

A single case report in JDDG, the weakest design for linking a drug to an adverse event: it can raise a question but cannot speak to how often this happens or whether the drug caused it. Bullous pemphigoid has an established association with other diabetes agents, notably DPP-4 inhibitors, which makes an incretin-era report worth logging. Without full text, the timing, any rechallenge and other exposures are unknown, so readers should regard it strictly as a hypothesis.